127 related articles for article (PubMed ID: 38401369)
1. Human papillomavirus negative high grade cervical lesions and cancers: Suggested guidance for HPV testing quality assurance.
Prétet JL; Arroyo Mühr LS; Cuschieri K; Fellner MD; Correa RM; Picconi MA; Garland SM; Murray GL; Molano M; Peeters M; Van Gucht S; Lambrecht C; Broeck DV; Padalko E; Arbyn M; Lepiller Q; Brunier A; Silling S; Søreng K; Christiansen IK; Poljak M; Lagheden C; Yilmaz E; Eklund C; Thapa HR; Querec TD; Unger ER; Dillner J
J Clin Virol; 2024 Apr; 171():105657. PubMed ID: 38401369
[TBL] [Abstract][Full Text] [Related]
2. HPV detection rates and histopathologic follow-up of patients with HSIL cytology in a large academic women's hospital laboratory.
Ashman D; Zhang H; Li J; Austin M; Wang T; Pradhan D; Zhao C
J Am Soc Cytopathol; 2020; 9(6):550-555. PubMed ID: 32475726
[TBL] [Abstract][Full Text] [Related]
3. Rescreening of high-risk HPV positive Papanicolaou tests initially screened as negative is a low yield procedure in the era of HPV genotyping.
Narkcham S; Mody DR; Jones A; Thrall MJ
J Am Soc Cytopathol; 2021; 10(6):558-564. PubMed ID: 34103275
[TBL] [Abstract][Full Text] [Related]
4. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
5. Aptima HPV messenger RNA testing and histopathologic follow-up in women with HSIL cytology: A study emphasizing additional review of HPV-negative cases.
Li A; Li J; Austin RM; Wang T; Ashman D; Zhang H; Matsko J; Zhao C
Cancer Cytopathol; 2021 Aug; 129(8):622-631. PubMed ID: 33764649
[TBL] [Abstract][Full Text] [Related]
6. [Effectiveness of Different Testing Strategies Applied for Cervical Cancer Screening in Shuangliu District, Chengdu City].
Zeng X; Li J; Kang LN; Yan LP; He Z; Liao GD; Xi MR; Chen MY
Sichuan Da Xue Xue Bao Yi Xue Ban; 2022 Sep; 53(5):896-903. PubMed ID: 36224694
[TBL] [Abstract][Full Text] [Related]
7. [Clinical value of p16
Song FB; Du H; Xiao AM; Wang C; Huang X; Yan PS; Liu ZH; Qu XF; Belinson JEROMEL; Wu RF
Zhonghua Fu Chan Ke Za Zhi; 2020 Nov; 55(11):784-790. PubMed ID: 33228350
[No Abstract] [Full Text] [Related]
8. Atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion: diagnostic performance, human papillomavirus testing, and follow-up results.
Srodon M; Parry Dilworth H; Ronnett BM
Cancer; 2006 Feb; 108(1):32-8. PubMed ID: 16136595
[TBL] [Abstract][Full Text] [Related]
9. The development of a quality assurance programme for HPV testing within the UK NHS cervical screening LBC/HPV studies.
Cubie HA; Moore C; Waller M; Moss S;
J Clin Virol; 2005 Aug; 33(4):287-92. PubMed ID: 16036178
[TBL] [Abstract][Full Text] [Related]
10. [Application of high-risk human papillomavirus testing in women with abnormal cytology].
Ou H; Bian ML; Zhang XY; Chen QY; Li M; Chen Y; Liu J
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2007 Oct; 29(5):608-11. PubMed ID: 18051714
[TBL] [Abstract][Full Text] [Related]
11. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].
Ronco G; Biggeri A; Confortini M; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Accetta G; Giordano L; Cogo C; Carozzi F; Gillio Tos A; Arbyn M; Mejier CJ; Snijders PJ; Cuzick J; Giorgi Rossi P
Epidemiol Prev; 2012; 36(3-4 Suppl 1):e1-72. PubMed ID: 22828243
[TBL] [Abstract][Full Text] [Related]
12. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.
Gilham C; Sargent A; Kitchener HC; Peto J
Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027
[TBL] [Abstract][Full Text] [Related]
13. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results.
Manos MM; Kinney WK; Hurley LB; Sherman ME; Shieh-Ngai J; Kurman RJ; Ransley JE; Fetterman BJ; Hartinger JS; McIntosh KM; Pawlick GF; Hiatt RA
JAMA; 1999 May; 281(17):1605-10. PubMed ID: 10235153
[TBL] [Abstract][Full Text] [Related]
14. High-risk Human Papillomavirus Messenger RNA Testing in Wet and Dry Self-collected Specimens for High-grade Cervical Lesion Detection in Mombasa, Kenya.
Islam JY; Mutua MM; Kabare E; Manguro G; Hudgens MG; Poole C; Olshan AF; Wheeler SB; McClelland RS; Smith JS
Sex Transm Dis; 2020 Jul; 47(7):464-472. PubMed ID: 32168174
[TBL] [Abstract][Full Text] [Related]
15. [HPV E6 and E7 mRNA combined with HPV 16 and 18 or 45 genotyping testing as a means of cervical cancer opportunistic screening].
Wang JJ; Dong J; Deng ZX; Wang PF; Zhang XX; Du Y
Zhonghua Fu Chan Ke Za Zhi; 2019 May; 54(5):301-306. PubMed ID: 31154710
[No Abstract] [Full Text] [Related]
16. Use of Fast Transfer Analysis Cartridges for Cervical Sampling and Real Time PCR Based High Risk HPV Testing in Cervical Cancer Prevention - a Feasibility Study from South India.
Vijayalakshmi R; Viveka TS; Malliga JS; Murugan K; Kanchana A; Arvind K
Asian Pac J Cancer Prev; 2015; 16(14):5993-9. PubMed ID: 26320486
[TBL] [Abstract][Full Text] [Related]
17. Negative computer-imaged ThinPrep Pap test and positive hybrid capture2 HPV co-testing results: A quality assurance review.
Rao R; Molina D; Halligan AM; Vakil B; Alperstein SA; Hoda RS
Diagn Cytopathol; 2015 Sep; 43(9):763-9. PubMed ID: 26173579
[TBL] [Abstract][Full Text] [Related]
18. Detection Rate of High-Grade Cervical Neoplasia and Cost-Effectiveness of High-Risk Human Papillomavirus Genotyping with Reflex Liquid-based Cytology in Cervical Cancer Screening.
Tay SK; Lin LE; Goh RC
Ann Acad Med Singap; 2017 Jul; 46(7):267-273. PubMed ID: 28821890
[TBL] [Abstract][Full Text] [Related]
19. Impact of high-risk Human Papillomavirus genotyping in cervical disease in the Northern region of Portugal: Real-world data from regional cervical cancer screening program.
Rosário A; Sousa A; Marinho-Dias J; Medeiros R; Lobo C; Leça L; Coimbra N; Tavares F; Baldaque I; Martins G; Monteiro P; Henrique R; Sousa H
J Med Virol; 2023 Jan; 95(1):e28414. PubMed ID: 36541747
[TBL] [Abstract][Full Text] [Related]
20. Performance of Aptima and Cobas HPV testing platforms in detecting high-grade cervical dysplasia and cancer.
Ge Y; Christensen P; Luna E; Armylagos D; Schwartz MR; Mody DR
Cancer Cytopathol; 2017 Aug; 125(8):652-657. PubMed ID: 28574670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
